Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin
Authors:
- 1 August 2018
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 168, 121-129
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseChest, 2016
- Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-AnalysisPLOS ONE, 2015
- Thrombosis: A major contributor to global disease burdenThrombosis Research, 2014
- Extended Use of Dabigatran, Warfarin, or Placebo in Venous ThromboembolismNew England Journal of Medicine, 2013
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismNew England Journal of Medicine, 2010
- Hemorrhagic Complications of Anticoagulant and Thrombolytic TreatmentChest, 2008
- Venous thromboembolism (VTE) in EuropeThrombosis and Haemostasis, 2007
- Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003
- Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous ThromboembolismNew England Journal of Medicine, 2003
- The Long-Term Clinical Course of Acute Deep Venous ThrombosisAnnals of Internal Medicine, 1996